Vaccine Hesitancy refers to the reluctance or refusal to vaccinate despite the availability of vaccines, posing a significant challenge to public health efforts to control and prevent vaccine-preventable diseases. Vaccine hesitancy can stem from various factors, including concerns about vaccine safety, efficacy, and necessity, as well as misinformation, complacency, and lack of trust in healthcare systems or authorities. One of the primary drivers of vaccine hesitancy is misinformation and myths surrounding vaccines, fueled by social media, conspiracy theories, and anti-vaccine movements. These sources often spread false or misleading information about vaccine ingredients, side effects, and alleged risks, leading to confusion and distrust among the public.
Fear of adverse reactions or side effects is another common reason for vaccine hesitancy. While serious adverse events following vaccination are rare, they can occur, leading some individuals to perceive vaccines as unsafe or unnecessary. Addressing these concerns requires transparent communication about vaccine safety data, risk-benefit assessments, and the importance of vaccination in preventing serious diseases. Complacency, or the perception that vaccine-preventable diseases are no longer a threat, can also contribute to vaccine hesitancy. In communities where disease incidence is low or eradicated, individuals may underestimate the importance of vaccination and delay or forgo immunization, leading to outbreaks and resurgence of preventable diseases. Lack of trust in healthcare providers, pharmaceutical companies, or government authorities can further exacerbate vaccine hesitancy. Historical injustices, systemic inequalities, and incidents of medical malpractice or corruption may erode trust in vaccination programs and undermine confidence in vaccine recommendations.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States